🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the battle against superbug strains of the pathogen, according to health experts.

An International Health Concern

Cases of gonorrhoea are escalating around the world, with figures suggesting more than 82 million new cases per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices currently available.”

Health officials are increasingly worried about the surge in drug-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Receive Clearance

Zoliflodacin, marketed under the name a brand name, was approved by the US Food and Drug Administration in recent days for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in close succession. This medication, which is employed against UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This milestone marks a significant shift in the treatment of superbug gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

According to results published in a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which involves an injection and a pill. The study included hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to license and sell the drug in numerous developing nations.

Doctors on the front lines have expressed optimism. The availability of a single-dose, oral treatment such as this is seen as a "critical tool" for public health efforts. This is viewed as vital to lessen the impact of the illness for individuals and to prevent the spread of untreatable gonorrhoea globally.